Skip to content

NAUWYNCK MARC

Active Private limited companyfounded 2001active for 25 yearsZeeweg 54, 8200 BrugesKBO/BCE: BE 0475.562.987

Lifetime

24 annual accounts with figures on one time axis
peak of €339,179 in 2021
€281,001▼ 4.1%
peak of €222,314 in 2021
€179,891▼ 7.0%
peak of €996,444 in 2024
€804,407▼ 19.3%
€415,531▲ 97.1%
Board2 names since 2016
2 directors and 1 other
Documentsfilings and deeds
20-03-202641 days before the deadline
2025micro format
Dividend €371,929Equity from €996,444 to €804,407Debts from €210,871 to €415,531

Key points

from the 2025 annual accounts

Equity

€804,407 ▼ 19.3%
996,4442024+179,891Profit-371,929Dividend804,4072025

NAUWYNCK MARC paid out €371,929 in dividends. That is 207% of the 2025 profit.

Turnover

≈ €420,000 estimated

The micro format states no turnover.

Debts

€415,531 ▲ 97.1%
Other debts
+203,504
Financial debts
+916
The rest
+240

Debts rose by €204,660 in 2025. A dividend stands under other debts on the balance sheet date until it is paid.

Liquidity

2.80 was 5.21 in 2024

Short-term debts rose from €210,871 to €408,531.

Filings

24 annual accounts since 2002
deadline20102020

The 2024 accounts came 16 days late. The other nine of the last ten were filed on time.

Position in the sector

€804,407

More equity than 90% of companies in human health. The sector median is €125,188, over 21,387 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 20,155 companies had the same profile as NAUWYNCK MARC has now. Each dot stands for 51 companies, two years later.

95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
  • Small
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 498,062 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.7% would go bankrupt within 24 months. In fact 1.8% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.4% 0.5%
3 0.6% 0.6%
4 0.7% 0.8%
5 0.9% 1.0%
6 1.4% 1.6%
7 1.7% 1.8%
8 1.9% 2.0%
9 3.1% 3.3%
10 5.9% 6.4%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 20,155 companies, not a prediction for NAUWYNCK MARC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
Director
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0475562987
Nauwynck Marc changes role from manager to director reappointed as director · Discharge granted to Nauwynck Marc · Gazette deed
appointed as manager Gazette deed
Incorporation published on 13-09-2001 · Gazette deed
All 38 events

Comparable companies

same main activity, similar in size and age
Company
NAUWYNCK MARC Bruges €1.2m €281,001 65.9% -
Dokter Lieven Vandeputte Bruges €1.1m €276,247 86.1% -
MEDICALE MARCIL Koksijde €1.2m €283,150 52.5% -
Dokters BEIRINCKX ANNEMIEKE - BEYNE ARNOLD Damme €1.3m €266,117 91.5% -
DOKTER BARBARA BUSSELS Ingelmunster €1.2m €285,995 85.1% -
DOKTER MATTENS Lommel €1.2m €266,542 74.3% -
Dr. Karen De Coninck, dermatologie Keerbergen €1.2m €280,550 4.3% -

These companies have the same main activity as NAUWYNCK MARC: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.1m and €1.3m, founded between 1999 and 2004.

Official details

Source: KBO
Status
Active since 03-09-2001Normal situation
Activity
Specialist medical practiceNACE 86220
Financial year end
30 September
Peppol
Reachable since 22-11-2025
Company details

Annual accounts to 30-09-2025

€1.2m▲ 1.0%
Filing
Filed on 20-03-2026, 41 days before the end of the filing period
Financials

Insights on NAUWYNCK MARC

NAUWYNCK MARC files the micro format. That format states no turnover. The gross margin rose from €141,889 in 2002 to €281,001 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about NAUWYNCK MARC

What is the company number of NAUWYNCK MARC?
The company number of NAUWYNCK MARC is 0475.562.987. The VAT number is the same number with BE in front: BE 0475.562.987.
Where is NAUWYNCK MARC based?
The registered office is at Zeeweg 54, 8200 Bruges.Company details
What does NAUWYNCK MARC do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of NAUWYNCK MARC?
NAUWYNCK MARC is a private limited company (BV).
When was NAUWYNCK MARC founded?
NAUWYNCK MARC was founded on 03-09-2001.
Is NAUWYNCK MARC still active?
Yes, NAUWYNCK MARC is an active enterprise in the KBO register.
What is the turnover of NAUWYNCK MARC?
The turnover in financial year 2025 is about €420,000. This figure is estimated from the gross margin of €281,001 and 31 comparable companies (NACE 86220). It probably lies between €370,000 and €590,000.Financials
Is NAUWYNCK MARC profitable?
In financial year 2025, NAUWYNCK MARC made a profit of €179,891.
Where can I find the annual accounts of NAUWYNCK MARC?
NAUWYNCK MARC filed 24 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of NAUWYNCK MARC due?
NAUWYNCK MARC must file the annual accounts for financial year 2026 by 30-04-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.